Diagnostics

Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease

09/11/2023

Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Two-year results from FISH&CHIPS, a real world, multi-center, retrospective clinical study with 90,553 patients conducted by the National Health Service (NHS) England were presented at the 2023 European Society of Cardiology (ESC) Congress meeting in Amsterdam by Principal Investigator, Dr. Tim Fairbairn, Consultant Cardiologist, Liverpool Heart and Chest Hospital. FFRCT (CCTA-derived Fractional…

Read More

Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson’s Disease

08/22/2023

Grant enables the application of Cantabio’s Redox DJ-1 ELISA platform for the quantification of specific oxidized states of DJ-1 in Parkinson’s disease patients’ bio-samples, such as iPSC-derived dopaminergic neurons, post-mortem brain tissue and plasma, for the development of a new biomarker potentially for early diagnosis of and tracking the progression of Parkinson’s disease Excerpt from…

Read More

HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

08/16/2023

Study Supported by $2.6 Million FDA Orphan Products Development Grant Excerpt from the Press Release: PRINCETON, N.J., Aug. 10, 2023 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment…

Read More

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

07/03/2023

Excerpt from the Press Release: WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate,…

Read More

Investment in Ontario drug discovery research will help develop new cancer medicines for patients

05/16/2023

OICR announces support for five projects through its Cancer Therapeutics Innovation Pipeline (CTIP) Excerpt from the Press Release: Ontario research teams investigating new ways to treat cancer are taking the crucial next steps to bring their discoveries to patients thanks to support from the Ontario Institute for Cancer Research (OICR). OICR announced it is funding…

Read More

SkylineDx and NeraCare enter a strategic partnership to advance precision medicine for early-stage melanoma

04/28/2023

Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies…

Read More

Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases

03/30/2023

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Mar. 24, 2023– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). This first patient was seen at the UT Southwestern Medical Center,…

Read More

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

12/09/2022

First patient receives brain-responsive neuromodulation for LGS, a severe and disabling childhood-onset epilepsy Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility…

Read More

Biological Dynamics collaborates on clinical utility studies to examine the impact of its early pancreatic cancer detection assay

11/29/2022

The company partners with QURE and Curta to assess value of early identification in high-risk cohorts Excerpt from the Press Release: SAN DIEGO, Nov. 22, 2022 /PRNewswire/ — Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the…

Read More

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure

11/11/2022

Multicenter Clinical Data from Five US sites Published in International Ophthalmology Excerpt from the Press Release: Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the…

Read More